Related Experiment Videos
[Chronic bronchitis. Value of RU 41740].
1Clinique de Pathologie respiratoire et de l'environnement, Centre Hospitalier intercommunal de Créteil.
Presse Medicale (Paris, France : 1983)
|July 27, 1988
Summary
RU 41740, a non-specific immunomodulator, effectively prevents airway infections in chronic bronchitis patients. This treatment reduces infectious episodes and antibiotic use, even in severe cases.
Area of Science:
- Respiratory Medicine
- Immunology
- Pharmacology
Context:
- Chronic bronchitis causes significant mortality and morbidity, with infections being a major complication.
- Bacterial resistance due to frequent antibiotic use is a growing concern in managing chronic bronchitis exacerbations.
- Pneumococci and Haemophilus influenza are common pathogens in acute-on-chronic bronchitis.
Purpose:
- To evaluate the efficacy of RU 41740, a non-specific immunomodulator, in preventing airway infections in chronic bronchitis patients.
- To assess the impact of RU 41740 on the frequency and duration of infectious episodes and antibiotic consumption.
Summary:
- Three double-blind, placebo-controlled trials demonstrated RU 41740's effectiveness in preventing airway infections.
- RU 41740 significantly reduced the number and duration of acute infectious episodes in patients with moderately advanced chronic bronchitis.
- The benefits of RU 41740 were observed across various stages of chronic bronchitis, including those with chronic respiratory failure and extensive bronchial dystrophy.
Impact:
- RU 41740 offers a promising strategy to reduce antibiotic reliance and combat bacterial resistance in chronic bronchitis management.
- The immunomodulator can improve patient outcomes by decreasing the incidence and severity of respiratory infections.
- This agent provides a therapeutic option for patients with chronic bronchitis, particularly those experiencing frequent infectious episodes.